Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 5:42 PM ET

Biotechnology

Company Overview of Idenix Pharmaceuticals Inc.

Company Overview

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of human viral diseases in the United States and France. Its primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). The company’s HCV discovery program focuses on nucleoside/nucleotide polymerase inhibitors, NS5A inhibitors, protease inhibitors, and non-nucleoside polymerase inhibitors. It is also developing non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency (HIV) virus type-1 and acquired immune deficiency syndrome (AIDS); and products and drug candidates for the treatment of p...

320 Bent Street

4th Floor

Cambridge, MA 02141

United States

Founded in 1998

84 Employees

Phone:

617-995-9800

Fax:

617-995-9801

Key Executives for Idenix Pharmaceuticals Inc.

Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Treasurer
Age: 36
Chief Medical Officer and Executive Vice President of Clinical Development
Age: 61
Chief Scientific Officer and Executive Vice President
Age: 49
Senior Vice President of Human Resources
Age: 57
Senior Vice President of Business & Corporate Development
Age: 53
Compensation as of Fiscal Year 2015.

Idenix Pharmaceuticals Inc. Key Developments

Idenix Pharmaceuticals Inc.(NasdaqGM:IDIX) dropped from Russell 2000 Index

Idenix Pharmaceuticals Inc. will be removed from the Russell 2000 Index.

Idenix Pharmaceuticals Inc.(NasdaqGM:IDIX) dropped from Russell 3000 Index

Idenix Pharmaceuticals Inc. will be removed from the Russell 3000 Index.

Idenix Pharmaceuticals Inc. Announces Resignation of Directors

Idenix Pharmaceuticals Inc. announced that in connection with the Merger and as contemplated by the Merger Agreement, each of Ronald C. Renaud, Jr., Wayne T. Hockmeyer, Thomas R. Hodgson, Tamar D. Howson, Denise Pollard-Knight, Charles A. Rowland, Jr. and Michael Wyzga tendered their respective resignations as directors from the company's board of directors and from all committees of the Board on which such directors served, effective as of the effective time of the Merger.

Similar Private Companies By Industry

Company Name Region
Terpenoid Therapeutics Incorporated United States
AdvanDx, Inc. United States
Oncofactor Corporation United States
Cenexys, Inc. United States
VisEn Medical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Idenix Pharmaceuticals Inc., please visit www.idenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.